ID   A2780ME
AC   CVCL_UJ38
DR   cancercelllines; CVCL_UJ38
DR   Wikidata; Q93311647
RX   PubMed=2429947;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; LPAM; Alkeran).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 05-10-23; Version: 8
//
RX   PubMed=2429947; DOI=10.20772/cancersci1985.77.9_941;
RA   Tsuruo T., Hamilton T.C., Louie K.G., Behrens B.C., Young R.C.,
RA   Ozols R.F.;
RT   "Collateral susceptibility of adriamycin-, melphalan- and
RT   cisplatin-resistant human ovarian tumor cells to bleomycin.";
RL   Jpn. J. Cancer Res. 77:941-945(1986).
//